Blood clotting caused by implanted medical devices is a severe and sometimes deadly complication impacting widely-used devices like hemodialysis catheters, central line catheters, venous access ports, and surgical drains1,2
The Silq treatment exhibits promising anti-thrombogenic properties with the protein complex fibrinogen, a factor that plays a key role in the blood clotting cascade and complications from implanted devices.3 Preventing the deposition of adhesion proteins like fibrinogen to implanted device surfaces is a proven method for anti-thrombogenic materials.4
1 Jaffer, I. H. et al. Medical device-induced thrombosis: what causes it and how can we prevent it? Journal of Thrombosis and Haemostasis, 13, S72–S81.
2 Wilson, A.C., et al. Engineering Approaches to Prevent Blood Clotting from Medical Implants. Archives in Biomedical Engineering and Biotechnology. (2019); 1(2)
3 Hu, W.J., et al. Molecular basis of biomaterial-mediated foreign body reactions. Blood. Vol. 98(4), 1231-1238
4 Wilson, C.J., et al. Mediation of Biomaterial–Cell Interactions by Adsorbed Proteins: A Review. Tissue Engineering. (2005) 11(1-2):1-18.